

### Neighborhood Pharmacy Authorization Criteria

Drug or Drug Class	Pharmacy Authorization Criteria
ADHD (Concerta and its generic equivalent, Ritalin LA, Vyvanse, Daytrana)	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with appropriate dose and duration of therapy using at least 2 generic agents including at least 1 methylphenidate product and 1 amphetamine product (of which 1 must be a long acting formulation) due to inadequate response and/or intolerance</li> </ul>
Aldara	<ul style="list-style-type: none"> <li>• Patient is being treated for cutaneous warts and</li> <li>• Patient has recently failed treatment due to inadequate outcome and/or intolerance with topical Salicylic acid, bi- or trichloroacetic acid and/or cryotherapy</li> </ul>
Angiotensin Receptor Blockers (Diovan, Benicar, Atacand, Avapro) and all combinations there of	<ul style="list-style-type: none"> <li>• Patient has experienced intolerance to an appropriate dose and duration of ACE-I therapy and</li> <li>• Patient has recently failed treatment using a combination of any two of the following three drugs due to inadequate response or intolerance*:               <ul style="list-style-type: none"> <li>○ Thiazide diuretics</li> <li>○ CCBs</li> <li>○ Betablockers</li> </ul> </li> </ul> <p><i>*not required for patients with DM, CHF or CKD</i></p>
Aranesp	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with Epogen or Procrit due to inadequate response and/or intolerance and meets the following criteria:               <ul style="list-style-type: none"> <li>○ Patient is being treated for chemotherapy induced anemia and currently has a documented hemoglobin level less than 12 g/dL or</li> <li>○ Patient is being treated for anemia related to chronic kidney failure and has a documented transferrin saturation level above 20%, ferritin level greater than 100ng/ml and hemoglobin less than 10 g/dL or</li> <li>○ Patient is being treated for anemia related to HIV therapy with zidovudine and currently has a documented endogenous serum erythropoietin level less than 500 mUnits/ml and a hemoglobin level less than 12 g/dL and is taking less than 4200mg or zidovudine per week or</li> <li>○ Patient is at risk for requiring an allogenic blood transfusion due to elective surgery and currently has a documented hemoglobin level between 10 and 12 g/dL and</li> </ul> </li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Baraclude	<ul style="list-style-type: none"> <li>• Patient is being treated for Chronic hepatitis B virus (nucleoside naïve), hepatitis B viremia during lamivudine therapy or lamivudine resistant hepatitis B and</li> <li>• Prescriber is Infectious Disease Specialist or Gastroenterologist and</li> <li>• Patient’s CrCl is above 50 cc/min or</li> <li>• Patient is considered high risk for hepatotoxicity with Hepsera or has demonstrated resistance to Hepsera</li> </ul>
Botox	<ul style="list-style-type: none"> <li>• Patient is being treated for neurologic disorder which has not responded to traditional therapy (e.g. oral antispasmodic agents like baclofen and dantrolene) or</li> <li>• Patient is being treated for migraine prophylaxis and has failed a recent trial with triptans and beta blockers or</li> <li>• Patient is being treated for blepharospasm or strabismus</li> </ul>
Byetta	<ul style="list-style-type: none"> <li>• Patient has not achieved adequate glucose control using a 2 gram per day dose of metformin and/or an appropriate dose of a sulfonyurea product and</li> <li>• Patient is not candidate for addition of thiazolidinedione or insulin therapy and</li> <li>• Patient is 18 years of age or older</li> </ul>
Chantix	<ul style="list-style-type: none"> <li>• Patient is enrolled in a supportive smoking cessation program and</li> <li>• Within the past 12 months patient has failed a 6 week trial with bupropion SR/XL due to inadequate outcome or has demonstrated intolerance to bupropion SR/XL or is not a candidate for Bupropion SR/XL due to co-morbid conditions such as seizure disorder, bipolar disorder or anorexia and</li> <li>• Within the past 12 months patient has failed a 6 week trial with nicotine gum or patch due to inadequate outcome or has demonstrated intolerance to nicotine gum or patch.</li> </ul>
Cimzia	<ul style="list-style-type: none"> <li>• Patient is being treated for moderate to severe RA and has failed a trial with at least one DMARD and/or Enbrel or Humira due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for Crohn’s disease and has failed a trial with conventional therapy such as DMARD, mesalamine and/or steroids due to inadequate response and/or intolerance</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Cymbalta	<ul style="list-style-type: none"> <li>• Patient is being treated for fibromyalgia, neuropathic pain or post herpetic neuralgia and has failed a recent trial with gabapentin dosed at 1800mg per day and at least 1 of the following drugs or drug classes: TCAs, SSRIs, cyclobenzaprine or pramipexole due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for depression and has failed a recent trial with at least two of the following drugs or drug classes: SSRIs, Bupropion XL/ER or venlafaxine ER/OSM due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for chronic pain or osteoarthritis and has failed a recent trial with at least two generic pain medications due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for anxiety disorder and has recently failed a trial with at least four of the following drugs or drug classes: Citalopram, fluoxetine, sertraline, paroxetine or any benzodiazepine due to inadequate response and/or intolerance</li> </ul>
DPP4 inhibitors (Januvia, Onglyza, Tradjenta and all combinations of these agents)	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with metformin (up to a dose of 2 grams per day) and SU due to inadequate response and/or intolerance</li> </ul>
Elidel	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with at least two generic topical steroid drugs due to inadequate response and/or intolerance</li> </ul>
Emend	<ul style="list-style-type: none"> <li>• Patient is currently receiving highly emetogenic chemotherapy and</li> <li>• Patient is experiencing acute N/V or delayed N/V within 24 hours of infusion and</li> <li>• Patient is currently receiving 5HT3 antagonist therapy and a corticosteroid regimen and</li> <li>• Ordering Provider is an oncologist and</li> <li>• Patient is not currently receiving either Orap or Propulsid</li> </ul>
Enbrel	<ul style="list-style-type: none"> <li>• Patient is being treated for moderate to severe RA, psoriatic arthritis, polyarticular course JRA or ankylosing spondylitis and has failed a recent trial with at least one DMARD due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for chronic moderate to severe plaque psoriasis and has failed a recent trial with at least one DMARD and/or phototherapy due to inadequate response and/or intolerance</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Epoetin alpha (Epogen and Procrit)	<ul style="list-style-type: none"> <li>• Patient is being treated for chemotherapy induced anemia and currently has a documented hemoglobin level less than 12 g/dL or</li> <li>• Patient is being treated for anemia related to chronic kidney failure and has a documented transferrin saturation level above 20%, ferritin level greater than 100ng/ml and hemoglobin less than 10 g/dL or</li> <li>• Patient is being treated for anemia related to HIV therapy with zidovudine and currently has a documented endogenous serum erythropoietin level less than 500 mUnits/ml and a hemoglobin level less than 12 g/dL and is taking less than 4200mg or zidovudine per week or</li> <li>• Patient is at risk for requiring an allogenic blood transfusion due to elective surgery and currently has a documented hemoglobin level between 10 and 12 g/dL</li> </ul>
Fluoroquinolones (Levaquin, Avelox)	<ul style="list-style-type: none"> <li>• Patient is being treated for CAP infection and has failed a recent trial with 3 of the following 5 drugs or drug classes: macrolide, 3<sup>rd</sup> generation cephalosporin, high dose amoxicillin, amox/clavulanic acid or doxycycline due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for non CAP infection and has failed a recent trial with 3 of the following 7 drugs or drug classes: macrolide, 3<sup>rd</sup> generation cephalosporin, high dose amoxicillin, amox/clavulanic acid, doxycycline, ciprofloxacin or SMZ-TMP due to inadequate response and/or intolerance</li> </ul>
Gilenya	<ul style="list-style-type: none"> <li>• Patient has failed adequate trial with at least one form of interferon and Copaxone due to inadequate response and/or intolerance</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

<p>Growth Hormone other than Omnitrope</p>	<ul style="list-style-type: none"> <li>● Patient has failed a recent trial with Omnitrope due to inadequate response and/or intolerance and meets the following criteria:               <ul style="list-style-type: none"> <li>○ Prescriber is endocrinologist and</li> <li>○ Patient is being treated for growth failure associated with chronic renal insufficiency and is in renal failure and is in good metabolic control or</li> <li>○ Patient is being treated for small for gestational age and has a birth weight and/or length that is at least 2SDS below the mean for gestational age and whose current height remains 2SDS below by two years of age or</li> <li>○ Patient is being treated for idiopathic short stature and whose current height is 2.25 SDS below the mean for his/her age and exhibits a growth rate that is unlikely to lead to an adult height within the normal genetic potential and other causes of short stature have been excluded or</li> <li>○ Patient is being treated for growth failure due to lack of GH secretion and patient has documented abnormally low values (&lt;10 ng/ml) of serum GH on two provocative tests and patient's height is 2 SDS below the mean height for normal children of the same age and conditions that depress GH (e.g. hypothyroidism, chronic nonendocrine disease) have been ruled out or</li> <li>○ Patient is being treated for Turner's Syndrome or Prader-Willi Syndrome or</li> <li>○ Patient is being treated for AIDs wasting or cachexia and has failed a recent trial with megestrol and is currently taking antiviral therapy or</li> <li>○ Patient is being treated for somatropin deficiency as a result of pituitary disease, hypothalamic disease, surgery, trauma or radiation therapy</li> </ul> </li> </ul>
<p>Humira</p>	<ul style="list-style-type: none"> <li>● Patient is being treated for moderate to severe RA, psoriatic arthritis or ankylosing spondylitis and has failed a recent trial with at least one DMARD due to inadequate response and/or intolerance or</li> <li>● Patient is being treated for Crohn's disease and has failed a trial with conventional therapy such as DMARD, mesalamine and/or steroids due to inadequate response and/or intolerance</li> </ul>
<p>Hyaluronic acid (Hyalgan, Euflexxa, Orthovisc, Supartz, Synvisc, Synvisc-One)</p>	<ul style="list-style-type: none"> <li>● Patient is being treated for documented moderate to severe osteoarthritis of the knee (radiographic reports required) and has failed a recent trial with 6 week course of full dose therapy with at least 2 generic NSAIDs and</li> <li>● Patient has failed to respond to a recent intra-articular injection of corticosteroid.</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

<p>Inhalation devices (Aerochamber, Optichamber)</p>	<ul style="list-style-type: none"> <li>• Patient is under age 12 and has failed a recent trial with an inhaled drug due to an inability to exercise proper inhalation technique or</li> <li>• Patient is 12 years old or older and has failed a recent trial with an inhaled drug due to an inability to exercise proper inhalation technique and/or the use of a MicroSpacer device.</li> </ul>
<p>Inhaled corticosteroid and long acting beta agonists combinations (Advair, Symbicort)</p>	<ul style="list-style-type: none"> <li>• Prescriber is Board certified Pulmonologist or Allergist or</li> <li>• Patient currently presents moderate persistent or severe persistent asthmatic symptoms requiring daily use of short acting beta agonists or</li> <li>• Patient currently presents with mild persistent asthma and has failed a recent trial with an appropriate dose and duration of therapy using an inhaled corticosteroid due to inadequate response and/or intolerance</li> </ul>
<p>Insulin Pens</p>	<ul style="list-style-type: none"> <li>• Patient is diagnosed with vision impairment severe enough to hinder accurate dosing using vials/syringes or</li> <li>• Patient is a full time student under the age of 18 and requires pen/cartridges for self administration during school sessions or</li> <li>• Patient is diagnosed with a condition which prohibits the coordination necessary to manipulate vials/syringes for accurate dosing</li> </ul>
<p>Intron A</p>	<ul style="list-style-type: none"> <li>• Patient is 18 years old or older and being treated for hairy-cell leukemia, follicular lymphoma, AID's related Kaposi's sarcoma or malignant melanoma or</li> <li>• Patient is 18 years old or older and being treated for condylomata acuminata and has failed a recent trial with conventional therapy such as cryosurgery, podofilox or imiquimod or</li> <li>• Patient is being treated for neoplastic or viral disease where the use of interferon-alfa A is supported by 2 clinical trials</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Itraconazole (Sporanox)	<ul style="list-style-type: none"> <li>• Patient is being treated for onychomycosis which has been confirmed by KOH preparation, nail biopsy or fungal culture (lab results required) or</li> <li>• Patient is being treated for recurring ingrown toenails secondary to onychomycosis requiring surgical repair/removal or</li> <li>• Patient has history of cellulitis or soft tissue involvement secondary to onychomycosis or</li> <li>• Patient has DM or other condition predisposing them to soft tissue infections in the extremities or</li> <li>• Patient has impaired immune system (e.g. HIV) or</li> <li>• Patient has refractory superficial dermatophyte infection or</li> <li>• Patient is being treated for systemic fungal infection</li> </ul>
Lamisil – Oral	<ul style="list-style-type: none"> <li>• Patient is being treated for onychomycosis which has been confirmed by KOH preparation, nail biopsy or fungal culture (lab results required) or</li> <li>• Patient is being treated for recurring ingrown toenails secondary to onychomycosis requiring surgical repair/removal or</li> <li>• Patient has history of cellulitis or soft tissue involvement secondary to onychomycosis or</li> <li>• Patient has DM or other condition predisposing them to soft tissue infections in the extremities or</li> <li>• Patient has impaired immune system (e.g. HIV) or</li> <li>• Patient has refractory superficial dermatophyte infection</li> </ul>
Lexapro	<ul style="list-style-type: none"> <li>• Patient is being treated for MDD or anxiety disorder and has failed a recent trial with at least 4 of the following 5 drugs or drug classes: citalopram, fluoxetine, sertraline, bupropion XL or any benzodiazepine due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for OCD or other disorder and has failed a recent trial with at least 4 of the following 5 drugs or drug classes: citalopram, fluoxetine, sertraline, fluvoxamine and/or clomipramine due to inadequate response and/or intolerance</li> </ul>
Lovaza	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial of a 4 gram per day dose of fish oil and an appropriate dose of either gemfibrozil or fenofibrate.</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Lupron	<ul style="list-style-type: none"> <li>• Patient is being treated for endometriosis and has failed a recent trial with NSAIDs and oral contraceptives due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for fibroids and has a Hemoglobin level below 10 g/dl despite receiving Iron therapy or</li> <li>• Patient is being treated for CPP with onset of secondary sexual characteristics earlier than age 8 in females or age 9 in males whose diagnosis has been confirmed by pubertal response to GnRH stimulation test and whose bone age is advanced 1 year beyond chronicle age and in whom presence of a tumor has been ruled out or</li> <li>• Patient is being treated for prostate cancer</li> </ul>
Lyrica	<ul style="list-style-type: none"> <li>• Patient is being treated for fibromyalgia, neuropathic pain or post herpetic neuralgia and has failed a recent trial with gabapentin dosed at 1800mg per day and at least 1 of the following drugs or drug classes: TCAs, SSRIs, cyclobenzaprine or pramipexole due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for seizures and has failed a recent trial with at least two of the following drugs or drug classes: carbamazepine, topiramate, valproic acid, gabapentin, oxcarbazepine, lamotrigine, tiagabine, zonisamide, levetiracetam or phenytoin due to inadequate response and/or intolerance</li> </ul>
Makena	<ul style="list-style-type: none"> <li>• Patient is pregnant and had a prior liveborn, single pregnancy of less than 37 weeks resulting from a spontaneous preterm delivery or spontaneous rupture of membranes and</li> <li>• Patient has a single gestation pregnancy</li> </ul>
Myobloc	<ul style="list-style-type: none"> <li>• See Botox</li> </ul>
Nutritional supplements	<ul style="list-style-type: none"> <li>• Patient is not eligible for coverage under the WIC program and</li> <li>• Patient is under the age of 12 and being treated for “failure to thrive” or</li> <li>• Patient is receiving nutritional supplement as their sole source of nutrition or</li> <li>• Patient is diagnosed with HIV or</li> <li>• Patient has experienced recent unplanned weight loss of at least 10% and has increased metabolic need resulting from trauma, malabsorption difficulties, ongoing cancer treatments, pulmonary insufficiency, low serum protein levels or anorexia Nervosa and licensed nutritionist or dietician has determined that sufficient caloric/protein intake is not obtainable through regular, liquefied or pureed foods</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Omnitrope	<ul style="list-style-type: none"> <li>• Prescriber is endocrinologist and</li> <li>• Patient is being treated for growth failure associated with chronic renal insufficiency and is in renal failure and is in good metabolic control or</li> <li>• Patient is being treated for small for gestational age and has a birth weight and/or length that is at least 2SDS below the mean for gestational age and whose current height remains 2SDS below by two years of age or</li> <li>• Patient is being treated for idiopathic short stature and whose current height is 2.25 SDS below the mean for his/her age and exhibits a growth rate that is unlikely to lead to an adult height within the normal genetic potential and other causes of short stature have been excluded or</li> <li>• Patient is being treated for growth failure due to lack of GH secretion and patient has documented abnormally low values (&lt;10 ng/ml) of serum GH on two provocative tests and patient's height is 2 SDS below the mean height for normal children of the same age and conditions that depress GH (e.g. hypothyroidism, chronic nonendocrine disease) have been ruled out or</li> <li>• Patient is being treated for Turner's Syndrome or Prader-Willi Syndrome or</li> <li>• Patient is being treated for AIDs wasting or cachexia and has failed a recent trial with megestrol and is currently taking antiviral therapy or</li> <li>• Patient is being treated for somatropin deficiency as a result of pituitary disease, hypothalamic disease, surgery, trauma or radiation therapy.</li> </ul>
Orencia	<ul style="list-style-type: none"> <li>• Patient is being treated for moderate to severe RA and has failed a trial with at least one DMARD and/or Enbrel or Humira due to inadequate response and/or intolerance</li> </ul>
Oxycontin	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with appropriately dosed Morphine Sulfate and fentanyl patches. Inadequate response to formulary long acting narcotic agents is not considered a reason for failure. Approval will not be granted unless a serious intolerance or contraindication to formulary long acting narcotic agents is documented. Serious intolerance does not include predictable side effects (nausea, sedation) that generally resolve within reasonable time periods.</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

<p>Pegylated Interferons (Pegasys and Peg-Intron)</p>	<ul style="list-style-type: none"> <li>• Patient is being treated for chronic hepatitis C not previously treated with pegylated interferon-alfa and</li> <li>• Patient has a documented baseline viral load level and current viral load level demonstrates progressive clinical improvement</li> </ul>
<p>Proton Pump Inhibitors (Nexium, Prevacid Solutabs, Aciphex, Dexilant)</p>	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with omeprazole dosed at 20mg twice daily and pantoprazole dosed at 40mg twice daily due to inadequate response and/or intolerance or</li> <li>• Patient is less than 2 years of age and cannot tolerate taking the contents of omeprazole capsules mixed in food</li> </ul>
<p>Protopic</p>	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with at least two generic topical steroid drugs due to inadequate response and/or intolerance</li> </ul>
<p>Provigil</p>	<ul style="list-style-type: none"> <li>• Patient is being treated for narcolepsy, obstructive sleep apnea syndrome (OSAS) or shift work sleep disorder (SWSD) and</li> <li>• Patient has failed a recent trial with appropriate dose and duration of therapy using at least 2 generic agents including at least 1 methylphenidate product and 1 amphetamine product (of which 1 must be a long acting formulation) due to inadequate response and/or intolerance</li> </ul>
<p>Remicade</p>	<ul style="list-style-type: none"> <li>• Patient is being treated for moderate to severe RA, psoriatic arthritis or ankylosing spondylitis and has failed a recent trial with at least one DMARD due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for moderate to severe Crohn's disease or ulcerative colitis and has failed a trial with conventional therapy such as DMARD, metronidazole, mesalamine and/or steroids due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for chronic moderate to severe plaque psoriasis and has failed a recent trial with at least one DMARD and/or phototherapy due to inadequate response and/or intolerance</li> </ul>
<p>Restatis</p>	<ul style="list-style-type: none"> <li>• Prescriber is ophthalmologist or optometrist and</li> <li>• Patient is being treated for keratoconjunctivitis sicca which has been confirmed by TBUT, ocular surface dye-staining or schirmer test and</li> <li>• Patient has failed recent trial with OTC ophthalmic lubricants, ophthalmic steroids, punctual plugs and/or moisture inserts due to inadequate response and/or intolerance</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Ribavirin	<ul style="list-style-type: none"> <li>• Patient is 18 years old or older and</li> <li>• Patient is being treated for chronic hepatitis C with compensated liver disease, and is receiving interferon alfa-2b or peginterferon alfa-2b and</li> <li>• Patient has a documented baseline viral load level and current viral load level demonstrates progressive clinical improvement and</li> <li>• Prescriber is a Gastroenterologist, Infectious Disease specialist, or physician experienced in the treatment of Hepatitis C and</li> <li>• Patient is not pregnant, does not have history of unstable cardiac disease or hemoglobinopathies and</li> <li>• Patient has a CrCl above 50mL/min</li> </ul>
Savella	<ul style="list-style-type: none"> <li>• Patient is being treated for fibromyalgia, neuropathic pain or post herpetic neuralgia and has failed a recent trial with gabapentin dosed at 1800mg per day and at least 1 of the following drugs or drug classes: TCAs, SSRIs, cyclobenzaprine or pramipexole due to inadequate response and/or intolerance</li> </ul>
Second generation Antipsychotics – Injectable (Risperdal Consta, Invega Sustenna, Zyprexa Relprevv)	<ul style="list-style-type: none"> <li>• Patient has had psychiatric related inpatient admission within the previous 6 months or</li> <li>• Patient has been stable on the requested therapy following previous psychiatric related inpatient admission</li> </ul>
Second generation Antipsychotics - ORAL (Abilify, Seroquel, Zyprexa, Saphris, Invega, Geodon, Latuda, Fanapt)	<ul style="list-style-type: none"> <li>• Patient has failed risperidone due to inadequate response, weight gain in excess of 7%, documented metabolic changes or EPS side effects or</li> <li>• Patient is being treated for condition for which risperidone is not FDA approved or</li> <li>• Patient has been stable on requested SGA for &gt;8 weeks <i>Also see Seroquel XR</i></li> </ul>
Sedative/Hypnotics (Lunesta, Rozerem, Ambien CR)	<ul style="list-style-type: none"> <li>• Patient has failed a trial with at least two of the following three generic and Formulary items due inadequate response and/or intolerance:             <ul style="list-style-type: none"> <li>○ Zolpidem</li> <li>○ Zaleplon</li> <li>○ Any Benzodiazepine</li> </ul> </li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Seroquel XR	<ul style="list-style-type: none"> <li>• Patient has failed risperidone due to inadequate response, weight gain in excess of 7%, documented metabolic changes, EPS side effects or</li> <li>• Patient is being treated for condition for which risperidone is not FDA approved or</li> <li>• Patient has been stable on requested SGA for &gt;8 weeks and</li> <li>• Patient has failed a recent trial with Seroquel IR due to inadequate response and/or intolerance</li> </ul>
Singulair	<ul style="list-style-type: none"> <li>• Patient is being treated for asthma and has recent history of short acting beta agonist use or</li> <li>• Patient is being treated for Allergic Rhinitis and has failed a recent trial with loratadine, cetirizine, fexofenadine and fluticasone nasal spray due to inadequate response and/or intolerance</li> </ul>
SNRI (Cymbalta, Effexor XR, Pristiq, Venlafaxine ER)	<ul style="list-style-type: none"> <li>• Patient is being treated for depression and has failed a recent trial with at least one SSRI and Bupropion XL/ER due to inadequate response and/or intolerance or</li> <li>• Patient is being treated for anxiety disorder and has recently failed a trial with at least four of the following drugs or drug classes: Citalopram, fluoxetine, sertraline, paroxetine or any benzodiazepine due to inadequate response and/or intolerance</li> </ul>
Statins (Lipitor, Crestor, Vytorin)	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with simvastatin 40mg due to inadequate response and/or intolerance</li> </ul>
Suboxone, Subutex film	<ul style="list-style-type: none"> <li>• Patient is being treated for opioid dependency and</li> <li>• Prescriber is duly licensed to prescribe Suboxone/Subutex and</li> <li>• Patient is receiving dose of 3 or fewer tablets per day and</li> <li>• Patient has failed recent trial with Suboxone/Subutex SL tablets due to inadequate response and/or intolerance</li> </ul>
Suboxone, Subutex SL tablets	<ul style="list-style-type: none"> <li>• Patient is being treated for opioid dependency and</li> <li>• Prescriber is duly licensed to prescribe Suboxone/Subutex and</li> <li>• Patient is receiving dose of 3 or fewer tablets per day</li> </ul>
Symlin	<ul style="list-style-type: none"> <li>• Patient is being treated for either Type I or II DM and</li> <li>• Prescriber is endocrinologist and</li> <li>• Patient has failed recent trial with combination of metformin, SU and insulin due to inadequate response and/or intolerance</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Synagis	<ul style="list-style-type: none"> <li>• Patient is less than 24 months and has had bronchopulmonary dysplasia or chronic lung disease requiring medication and/or oxygen within the previous 6 months or</li> <li>• Patient is less than 24 months with hemodynamically significant congenital heart disease with congestive heart failure, cardiac medication, anticipated heart disease, oxygen requirement, pulmonary hypertension or cyanotic defects or</li> <li>• Patient was born at less than 29 weeks gestation and will be less than 12 months old at the beginning of the RSV season or</li> <li>• Patient was born between 29 and 32 weeks gestation and will be less than 6 months old at the beginning of the RSV season or</li> <li>• Patient was born between 32 and 35 weeks gestation, will be less than 90 days old at the beginning of the RSV season and attended child care and/or has siblings less than 5 years of age* (*these children receive Synagis until age 3 months)</li> </ul>
Terbinafine	See Lamisil
Thiazolidinediones (Actos, Avandia and all combinations thereof)	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with metformin (up to a dose of 2 grams per day) and SU due to inadequate response and/or intolerance</li> </ul>
Tretinoin (Retin A) topical	<ul style="list-style-type: none"> <li>• Patient is being treated for acne vulgaris or pre-cancerous or cancerous skin lesions</li> </ul>
Triptans (Maxalt, Frova, Axert, Relpax, Amerge)	<ul style="list-style-type: none"> <li>• Patient has failed a recent trial with sumatriptan and naratriptan due to inadequate response and/or intolerance.</li> </ul> <p><i>Sumatriptan is limited to 6 doses per month. Approval of naratriptan requires failure on sumatriptan.</i></p>
Tretinoin topical	<ul style="list-style-type: none"> <li>• Patient is under the age of 40 or</li> <li>• Patient is being treated for acne</li> </ul>
Tysabri	<ul style="list-style-type: none"> <li>• Patient is being treated for relapsing MS and has experienced a relapse within the previous 12 months and has failed a recent trial with interferon and/or Copaxone due to inadequate response and/or intolerance</li> </ul>
Victoza	<ul style="list-style-type: none"> <li>• Patient has not achieved adequate glucose control using a 2 gram per day dose of metformin and/or an appropriate dose of a sulfonyurea product and</li> <li>• Patient is not candidate for addition of thiazolidinedione or insulin therapy and</li> <li>• Patient is 18 years of age or older</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

<p>Weight loss agents – Initial RX (phentermine, OTC Alli)</p>	<ul style="list-style-type: none"> <li>● Patient is enrolled in weight reduction program and nutritional counseling program and meets the following criteria:             <ul style="list-style-type: none"> <li>○ Patient has BMI equal to, or above, 27 and 1 or more very high absolute risk factors (e.g. CHD or atherosclerotic disease, Type-2 Diabetes, sleep apnea) or</li> <li>○ Patient has BMI equal to, or above, 27 and 3 or more high absolute risk factors (e.g. Cigarette smoking, hypertension (&gt;140/90), high risk LDL (&gt;160 mg/dL), low HDL (&lt;40mg/dL), fasting plasma glucose between 100 and 125 mg/dL, family history of premature CHD) or</li> <li>○ Patient has BMI equal to, or above, 30</li> </ul> </li> </ul>
<p>Weight loss agents - renewal RX (phentermine, OTC Alli)</p>	<ul style="list-style-type: none"> <li>● Patient is enrolled in weight reduction program and nutritional counseling program and meets the following criteria:             <ul style="list-style-type: none"> <li>○ Patient has BMI equal to, or above, 27 and 1 or more very high absolute risk factors (e.g. CHD or atherosclerotic disease, Type-2 Diabetes, sleep apnea) or</li> <li>○ Patient has BMI equal to, or above, 27 and 3 or more high absolute risk factors (e.g. Cigarette smoking, hypertension (&gt;140/90), high risk LDL (&gt;160 mg/dL), low HDL (&lt;40mg/dL), fasting plasma glucose between 100 and 125 mg/dL, family history of premature CHD) or</li> <li>○ Patient has BMI equal to, or above, 30 and</li> <li>○ Patient has lost 4 or more pounds within 4 weeks of initial RX</li> <li>○ Patient has received less than 6 months of therapy within the previous year</li> </ul> </li> </ul>
<p>Xolair</p>	<ul style="list-style-type: none"> <li>● Patient is being treated for severe persistent asthma and</li> <li>● Patient is under the care of an Allergist/Pulmonologist and</li> <li>● Patient is 12 years old (or older) and</li> <li>● Patient has been receiving first line asthma maintenance therapy according to NIH recommendations for at least 6 months and has failed therapy due to inadequate response and/or intolerance and</li> <li>● Patient has been actively enrolled in Neighborhood case management for at least 3 months and</li> <li>● Patient has not smoked within previous 6 months and</li> <li>● Patient has IgE level between 30 and 700 IU/ml</li> </ul>

### Neighborhood Pharmacy Authorization Criteria

Zyvox	<ul style="list-style-type: none"><li>• Patient is under the care of infectious disease specialist and</li><li>• Patient is being treated for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) or multidrug resistant <i>Streptococcus pneumonia</i> (MDRSP) infection or</li><li>• Patient is being treated for vancomycin-resistant <i>Enterococcal faecium</i> infection or</li><li>• Patient is continuing Zyvox therapy started as a hospital inpatient</li></ul>
General Medical Necessity Criteria for drugs without drug or drug class specific criteria	<ul style="list-style-type: none"><li>• Patient has failed a recent trial with at least one generic and/or Formulary drugs available for treatment of the identified condition, disorder or disease due to inadequate response and/or intolerance and meets the following:<ul style="list-style-type: none"><li>○ Use of the requested drug has final approval from the FDA and</li><li>○ Use of the requested drug is supported by scientific evidence that permits reliable conclusions to be drawn about the effect of the treatment on health outcomes and</li><li>○ The available evidence and clinical documentation supports the conclusion that the treatment improves net health outcomes and is as beneficial as any established alternative or more beneficial than existing alternatives for an identifiable subgroup of individuals and</li><li>○ The available evidence and clinical documentation supports the conclusion that the treatment is as safe as existing alternatives, or if the treatment is less safe than existing alternatives it is efficacious for patients who are not adequately treated with existing alternatives</li></ul></li></ul>